Switching from warfarin to rivaroxaban: A safer, modern approach

Warfarin, a vitamin K antagonist (VKA), has long been the standard treatment for atrial fibrillation (AFib), supported by strong evidence for preventing stroke and thrombotic events. However, its clinical use presents challenges such as slow onset, numerous drug and food interactions, and an increased risk of major bleeding, necessitating frequent monitoring.

The introduction of non-VKA oral anticoagulants (NOACs) has significantly improved AFib management, offering better safety profiles, fewer interactions, and enhanced patient adherence.

AFib is the most common sustained cardiac arrhythmia in adults globally, associated with significant morbidity, mortality, and a rising economic burden. The condition’s prevalence, currently estimated between 2% and 4% in adults, is expected to increase due to aging populations and improved diagnostics. Age, hypertension, diabetes, and heart failure are major risk factors, contributing to its growing prevalence. Diagnosis requires ECG documentation showing irregular heart rhythms without distinct P-waves.

To access the article and quiz, go to https://www.medicalacademic.co.za/ courses/

This CPD activity was made possible by Sanofi. The content was independently sourced.